Insight into Dexamethasone’s Benefits in Severe COVID-19
Insight into Dexamethasone’s Benefits in Severe COVID-19
The steroid’s exceptional performance in early results from the RECOVERY clinical trial in the United Kingdom is a rational outcome of the drug’s anti-inflammatory effects, experts say.
Insight into Dexamethasone’s Benefits in Severe COVID-19
Insight into Dexamethasone’s Benefits in Severe COVID-19

The steroid’s exceptional performance in early results from the RECOVERY clinical trial in the United Kingdom is a rational outcome of the drug’s anti-inflammatory effects, experts say.

The steroid’s exceptional performance in early results from the RECOVERY clinical trial in the United Kingdom is a rational outcome of the drug’s anti-inflammatory effects, experts say.

pharmaceuticals
Judge Rules Unreported Clinical Trial Data Must Be Made Public
Judge Rules Unreported Clinical Trial Data Must Be Made Public
Amy Schleunes | Feb 26, 2020
The sponsors of upwards of 1,000 clinical trials may be forced to publish data that have gone unpublished over a 10-year period.
Biogen, Eisai End Two Late-Stage Trials for Alzheimer’s Treatment
Biogen, Eisai End Two Late-Stage Trials for Alzheimer’s Treatment
Emily Makowski | Sep 16, 2019
The widely expected move comes months after the companies scrapped trials of another Alzheimer’s drug.
How the Brain Changes on Ketamine: A Live Animal Study
How the Brain Changes on Ketamine: A Live Animal Study
Ruth Williams | Apr 11, 2019
The drug promotes and sustains brain cell connectivity in mice, reversing the effects of chronic stress.
Mopping Up Excess Chemotherapy Drugs
Mopping Up Excess Chemotherapy Drugs
Ruth Williams | Apr 1, 2019
A prototype in-vein device would collect toxic medications before they reach healthy tissues.
Lasker Awards Recognize Work on Histones, Anesthesia, RNA
Lasker Awards Recognize Work on Histones, Anesthesia, RNA
Shawna Williams | Sep 11, 2018
This year’s winners are C. David Allis, Michael Grunstein, John Glen, and Joan Steitz.
FDA Approves First Marijuana-Derived Drug
FDA Approves First Marijuana-Derived Drug
Shawna Williams | Jun 25, 2018
As the CBD-based medication enters the market, the agency promises a crackdown on producers of cannabidiol products that make unproven claims.
Researchers Getting Smarter About Pairing Cancer Treatments
Researchers Getting Smarter About Pairing Cancer Treatments
Anna Azvolinsky | Apr 1, 2018
Multidrug combinations lead to better results for cancer patients, but efficiently identifying them is proving difficult.
Infographic: Cancer Drug Pairings
Infographic: Cancer Drug Pairings
Anna Azvolinsky | Mar 31, 2018
Researchers use several different strategies to deliver a one-two punch.
Pfizer to Halt Alzheimer’s and Parkinson’s Drug Research
Pfizer to Halt Alzheimer’s and Parkinson’s Drug Research
Jim Daley | Jan 7, 2018
The company’s recent effort to find new treatments for Alzheimer’s ended in disappointment.
Clinical Trial Reporting for Pharma-Sponsored Trials Shows Improvement
Clinical Trial Reporting for Pharma-Sponsored Trials Shows Improvement
Diana Kwon | Dec 4, 2017
The Good Pharma Scorecard finds some big pharmaceutical companies are meeting legal standards for disclosing results—but many studies still go unreported.
RNA Interference Drug Excels in Clinical Trials to Treat Rare Disorder
RNA Interference Drug Excels in Clinical Trials to Treat Rare Disorder
Katarina Zimmer | Nov 3, 2017
If approved, patisiran will be the first RNAi therapeutic on the market. 
Puerto Rico’s Hurricane Damage May Mean Drug Shortages
Puerto Rico’s Hurricane Damage May Mean Drug Shortages
Ashley P. Taylor | Oct 11, 2017
Three weeks after Hurricane Maria hit the island, pharmaceutical plants are not back up to speed.
Opinion: Token Pharmacovigilance
Opinion: Token Pharmacovigilance
Peter Doshi | May 23, 2017
A US government website for collecting reports of side effects associated with vaccines is broken. Why has no one noticed?
Johnson & Johnson to Acquire Swiss Biotech Firm for $30 Billion
Johnson & Johnson to Acquire Swiss Biotech Firm for $30 Billion
Joshua A. Krisch | Jan 26, 2017
With its purchase of Actelion, Johnson & Johnson’s acquires experimental treatments for pulmonary arterial hypertension and several rare diseases.
Takeda to Buy Cancer Drug Maker Ariad for $5.2 Billion
Takeda to Buy Cancer Drug Maker Ariad for $5.2 Billion
Joshua A. Krisch | Jan 9, 2017
The pharma giant’s purchase of the US firm includes the acquisition of investigative cancer drugs.
Drug Approval Timeline Same as 20 Years Ago
Drug Approval Timeline Same as 20 Years Ago
Kerry Grens | Jan 9, 2017
A report finds that new medications still take about 12 years to go from patent to patient.